BridgeBio Shares Pop Again As Phase III Thyroid Drug Exceeds Investor Expectations
Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a genetic thyroid disorder.
BridgeBio Shares Pop Again As Phase III Thyroid Drug Exceeds Investor Expectations Read More »
